Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Blood Advances|June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AMLAnna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
JAMA Oncology|November 21, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical TrialElias Jabbour, Vivian G Oehler, Paul B Koller, et al.
BMC Cancer|April 4, 2018
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemiaEhab Atallah, Charles A Schiffer, Kevin P Weinfurt, et al.
Leukemia & Lymphoma|March 20, 2023
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemiaRyan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2019
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML StudyJenny L Smith, Rhonda E Ries, Tiffany Hylkema, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
JAMA Oncology|November 12, 2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical TrialEhab Atallah, Charles A Schiffer, Jerald P Radich, et al.
Blood|November 15, 2021
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosisHelong Zhao, Anthony D Pomicter, Anna M Eiring, et al.
Pageof 11